| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T96721 | ||||
| Target Name | Vascular endothelial growth factor | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | SU5416 | Drug Info | IC50 = 40 nM | [552338] | |
| TAK-593 | Drug Info | Ki = 0.95~3.2 nM | [553086] | ||
| Bevasiranib | Drug Info | IC50 = 0.95~3.2 nM | |||
| Avastin+/-Tarceva | Drug Info | IC50 = 95000 nM | [552871] | ||
| References | |||||
| Ref 552338 | SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 1;102(3):795-801. Epub 2003 Mar 20. | ||||
| Ref 553086 | Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. doi: 10.1021/bi101777f. Epub 2011 Jan 10. | ||||
| Ref 552871 | Recent advances in the research of HIV-1 RNase H inhibitors. Mini Rev Med Chem. 2008 Oct;8(12):1243-51. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.